Skip to main content
. Author manuscript; available in PMC: 2010 Sep 29.
Published in final edited form as: J Neuroimmunol. 2009 Aug 3;214(1-2):93–100. doi: 10.1016/j.jneuroim.2009.07.006

Figure 1.

Figure 1

Suppression of SAP in B7-2 deficient NOD mice by FTY720. Animals were divided into 3 groups: (1) water (n = 11); (2) FTY720 at 0.3 mg/kg (n = 5); and (3) FTY720 at 1.0 mg/kg (n = 10). Daily oral administration was initiated at 7 months of age and continued for 4 weeks. A. Clinical scores. The median clinical score at 8 mo was 2.5 for water-treated group, 2.0 for FTY720 (0.3 mg/kg) and 0.75 for FTY720 (1 mg/kg); * p <0.0006 for FTY720 (1 mg/kg) vs water (Mann-Whitney test). B. Hindlimb and forelimb grip strength measurements. *p <0.01 for FTY720 (1 mg/kg) vs water. C, D. Examples and summary of sciatic nerve electrophysiology. Distal latency (DL), conduction velocity (CV), and amplitude (Amp) of sciatic compound muscle action potentials (CMAPs) were measured [n =7 mice for FTY720 (1 mg/kg) group, and n =6 for water-treated ones; *p <0.02; **p <0.01]. Subsequent analysis was carried out in FTY720 (1 mg/kg) group only.